Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

8.155 -0.175 (-2.10%)
Streaming Delayed Price Updated: 3:03 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Zevra (ZVRA) Q3 2025 Earnings Call Transcript ↗
Zevra (ZVRA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
News headline image
A Look at Zevra Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock ↗
 
Via Benzinga
News headline image
Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors
Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early... 
Via MarketMinute
News headline image
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks — Zevra Therapeutics, Inc. (NASDAQGS: ZVRA) to Present New MIPLYFFA Data at ICIEM, Poster Earns Best Poster Award
Via Investor Brand Network
News headline image
Crude Oil Down 1%; Performance Food Group Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed. ↗
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations. 
Via Investor's Business Daily
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zevra Revenue Jumps 486 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
How Zevra's Miplyffa Could Transform Investment Strategies ↗
HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength. 
Via Benzinga
News headline image
This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? ↗
Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results. 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Zevra Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.